

Elecsys® GAAD

Elecsys® GAAD is intended as an aid in diagnosis of early stage Hepatocellular Carcinoma (HCC).

Elecsys® GAAD result

negative

Elecsys® GAAD score

(Score range 0-10)

2.12

Identifying information

Operator name

Patient identifier

Date
02-SEP-2025

Time
12:27:37 CEST

Gender	Male
Age in years	71

Test name	Test result	Range
Elecsys® AFP	3.33 ng/ml	2.72-1210 ng/ml
Elecsys® PIVKA-II	25.4 ng/ml	4.5-12000 ng/ml

Result interpretation

The calculated Elecsys® GAAD score Z is evaluated with a predefined cutoff 2.57. If $Z \geq 2.57$ then the Elecsys® GAAD result is positive, indicating a patient should be further evaluated by imaging and other HCC diagnostic testing. Elecsys® GAAD score (Z) increases with increasing risk of HCC.

Sensitivity and specificity

At the cutoff of 2.57, clinical performance of Elecsys® GAAD score in a multicentric validation cohort (156 HCC cases and 208 controls) is sensitivity of 78.9% for early stage HCC (BCLC stage 0 and A), sensitivity of 86.5% for all stage HCC (BCLC stage 0, A, B, C and D), and a specificity of 91.3% in cirrhotic or non-cirrhotic liver disease controls.

For further information, please access the Elecsys® GAAD method sheet on eLabDoc.roche.com, material number "GAAD 09342192001".